| Sharon Edmondson, PHARMD | |
|
969 Us Highway 80 W, Demopolis, AL 36732-4102 | |
| (334) 289-9897 | |
| Not Available |
| Full Name | Sharon Edmondson |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 969 Us Highway 80 W, Demopolis, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417392507 | NPI | - | NPPES |
| 19483 | Other | AL | STATE LICENSE |
| Mailing Address | Practice Location Address |
|---|---|
| Sharon Edmondson, PHARMD 5417 Whisper Wood Cir, Hoover, AL 35226-5000 Ph: (205) 585-6079 | Sharon Edmondson, PHARMD 969 Us Highway 80 W, Demopolis, AL 36732-4102 Ph: (334) 289-9897 |
News Archive
Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced first patient enrollment in the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical study at Na Homolce Hospital, Prague, Czech Republic, by study investigator Petr Neuzil, M.D.
A way of using machine learning to more accurately identify patients with a mix of psychotic and depressive symptoms has been developed by researchers at the University of Birmingham.
Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, recently sponsored a Satellite Symposium at the World Meeting of Melanoma/Skin Cancer Centers in Berlin, Germany. The session, titled "Regional Therapeutic Options for Metastatic Melanoma," was held on Friday, November 20 and featured updates and observations on a variety of current therapies by clinical leaders in the field.
Since its passage in March 2010, President Obama's health care reform package has been controversial. The latest Associated Press poll, however, finds that the percent of Americans who approve of the way Mr. Obama is handling health care has hit a new high.
Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane‐disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
› Verified 5 days ago
Mr. John Ashton Beaudry, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 312 Us Highway 80 E, Demopolis, AL 36732 Phone: 334-289-3657 | |
Teresa Boone, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 951 Us Highway 80 W # B, Demopolis, AL 36732 Phone: 334-289-8989 | |
Raymond Leon Boone, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 951 Us Highway 80 W # B, Demopolis, AL 36732 Phone: 334-289-9982 Fax: 334-289-3276 | |
Caitlin Moore, PHARMD., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 969 Us Highway 80 W, Demopolis, AL 36732 Phone: 334-289-9897 | |
Trameika M. Hawkins, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 505 Us Highway 80 W Ste A, Demopolis, AL 36732 Phone: 334-287-1200 Fax: 334-287-0509 | |
Dr. Jamie Lynn Tucker, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1107 Lillian Lane, Demopolis, AL 36732 Phone: 334-507-8266 |